Cyclacel Pharmaceuticals, Inc. (CYCC) - NASDAQ
  • Tue, Jun. 21, 11:16 AM
    • Thinly traded nano cap MYOS RENS (MYOS +12.2%) heads north on a 6x surge in volume, albeit on turnover of only 79K shares, adding to yesterday's 26% move on 19x higher volume. No particular news accounts for the action, but some other tiny firms have shown similar price action lately, some explained, some not.
    • MYOS RENS develops and commercializes biotherapeutic and bionutritional products that improve muscle mass. Its lead product is a nutritional supplement called Fortetropin, a protein/lipid complex consisting of ~250 proteins, ~50 lipids, a range of peptides and other unnamed molecules isolated from egg yolks.
    • Recent bullish price action: (PULM -9.1%)(BLPH -7.7%)(IMNP +35%)(JAGX +1.4%)(BSPM -12.1%)(CYCC +6.3%)(CBIO -6.2%)(GBIM -5.3%)
    | Tue, Jun. 21, 11:16 AM
  • Thu, Jun. 16, 12:02 PM
    • Thinly traded nano cap Pulmatrix (PULM +31.9%) jumps on a whopping 47x surge in volume, albeit on turnover of 992K shares. The stock is up almost 70% since Tuesday. No particular news accounts for the bullish behavior, although other small biotechs are experiencing similar action.
    • The company has three product candidates in its pipeline, none further than Phase 1. Last month, it announced that it had completed dosing in healthy volunteers in a Phase 1 pharmacokinetic study of PUR0200, its candidate for the treatment of bronchospasm in patients with chronic obstructive pulmonary disease (COPD), with the aim of showing bioequivalence with a currently approved product.
    • Other pipeline programs are PUR1900 for cystic fibrosis and PUR1500 for ideopathic pulmonary fibrosis.
    • Tickers showing recent price spikes (some explained, some not): (BLPH -1.9%)(IMNP -6%)(JAGX -5.8%)(BSPM +9.2%)(CYCC -7.6%)(CBIO)(GBIM +30.5%)
    | Thu, Jun. 16, 12:02 PM | 4 Comments
  • Thu, Jun. 9, 12:19 PM
    • Bellerophon Therapeutics (BLPH +73.1%) rockets up on a whopping 210x surge in volume. No particular news accounts for the move, but this is yet another recent price spike in the biotech nano cap space.
    • Recent up moves include: Immune Pharmaceuticals (IMNP -2.5%), Jaguar Animal Health (JAGX +89.4%), Biostar Pharmaceuticals (BSPM -23.4%) and Cyclacel Pharmaceuticals (CYCC -0.6%).
    • The action may be attractive to some, but these types of moves are notorious for quick round-trips.
    | Thu, Jun. 9, 12:19 PM | 1 Comment
  • Tue, Jun. 7, 12:50 PM
    | Tue, Jun. 7, 12:50 PM | 5 Comments
  • Mon, Jun. 6, 12:48 PM
    | Mon, Jun. 6, 12:48 PM
  • Mon, Jun. 6, 11:56 AM
    • Ultra-thinly traded Cyclacel Pharmaceuticals (CYCC +66.3%) heads north on a whopping 170x surge in volume, albeit on turnover of ~2.1M shares, in response to its announcement of data from a Phase 1 clinical trial assessing sapacitabine and seliciclib in heavily pretreated patients with advanced solid tumors. The results were presented today at ASCO16 in Chicago.
    • The regimen was administered sequentially (Part 1) and together (Part 2) in 67 subjects. Antitumor activity was observed in a subgroup of 45 (67.2%) patients with breast, ovarian and pancreatic cancers who were BRCA mutation-positive. The overall disease control rate (DCR) was 35.6% (n=16/45) consisting of one complete responder, five partial responders and 10 with stable disease. In Part 1, the DCR was 37.5% (n=6/16) but eased a bit to 32.1% (n=9/28) in Part 2. The overall response rate was 13.3% (n=6/45), although the press release states 11%.
    • Sapacitabine, currently in Phase 3 development in acute myeloid leukemia, is an oral nucleoside analogue prodrug whose metabolite, CNDAC, arrests the cell cycle by breaking up DNA. Orally available seliciclib, currently in Phase 2 for myelodysplastic syndrome , inhibits the enzymes CDK2 and CDK9, which play key roles in cell growth, survival and cell cycle control.
    | Mon, Jun. 6, 11:56 AM
  • Mon, Jun. 6, 11:01 AM
    | Mon, Jun. 6, 11:01 AM
  • Fri, May 27, 5:13 PM
    • With the aim of regaining compliance with Nasdaq listing requirements, thinly traded nano cap Cyclacel Pharmaceuticals (NASDAQ:CYCC) reverse splits its common stock 1:12 effective at 5:00 pm ET today. Trading in post-split shares will commence on Tuesday, May 31.
    | Fri, May 27, 5:13 PM
  • Thu, May 12, 2:59 AM
    • Cyclacel Pharmaceuticals (NASDAQ:CYCC): Q1 EPS of -$0.09
    • Revenue of $0.14M (-72.5% Y/Y)
    • Press Release
    | Thu, May 12, 2:59 AM
  • Wed, May 11, 4:20 PM
    • Cyclacel Pharmaceuticals (NASDAQ:CYCC): Q1 EPS of -$0.09
    • Cash and cash equivalents of $17.1M.
    • Press Release
    | Wed, May 11, 4:20 PM
  • Thu, Mar. 24, 4:12 PM
    • Cyclacel Pharmaceuticals (NASDAQ:CYCC): Q4 EPS of -$0.10 misses by $0.02.
    • Revenue of $0.43M (+72.0% Y/Y) misses by $0.08M.
    • Press Release
    | Thu, Mar. 24, 4:12 PM | 1 Comment
  • Nov. 30, 2015, 12:49 PM
     
    | Nov. 30, 2015, 12:49 PM | 8 Comments
  • Nov. 30, 2015, 9:26 AM
    | Nov. 30, 2015, 9:26 AM | 1 Comment
  • Nov. 12, 2015, 5:00 PM
    • Cyclacel Pharmaceuticals (NASDAQ:CYCC): Q3 EPS of -$0.08
    • Revenue of $0.74M (+2.8% Y/Y)
    | Nov. 12, 2015, 5:00 PM
  • Aug. 12, 2015, 7:43 AM
    • Cyclacel Pharmaceuticals (CYCC -3.4%) Q2 results: Revenues: $0.3M (-25.0%); R&D Expense: $2.6M (-42.2%); SG&A: $1.3M (-7.1%); Operating Loss: ($3.6M) (+35.7%); Net Loss: ($3.3M) (+31.3%); Loss Per Share: ($0.10) (+54.5%); Quick Assets: $26.9M (+11.2%).
    • No guidance given.
    | Aug. 12, 2015, 7:43 AM
  • Aug. 11, 2015, 4:15 PM
    • Cyclacel Pharmaceuticals (NASDAQ:CYCC): Q2 EPS of -$0.10
    • Revenue of $0.3M (-14.3% Y/Y)
    | Aug. 11, 2015, 4:15 PM
Company Description
Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Its most advance product candidate, is the subject of SEAMLESS, a phase 3 trail... More
Sector: Healthcare
Industry: Biotechnology
Country: United States